Veru announces acceptance of two abstracts for presentation at the american society of clinical oncology (asco) 2021 annual meeting

-- presentation of phase 2 trial clinical trial data from patients with ar+er+her2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (ar) in breast cancer tissue -- -- presentation of phase 1b/2 updated clinical trial results of sabizabulin (veru-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer --
VERU Ratings Summary
VERU Quant Ranking